MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Veracyte, Inc. - Common Stock (NQ:VCYT)

43.80 +0.50 (+1.15%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Veracyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025
From Veracyte, Inc.
Via Business Wire
News headline image
Demystifying Veracyte: Insights From 7 Analyst Reviews ↗
 
Via Benzinga
News headline image
Exploring NASDAQ:VCYT's high growth characteristics. ↗
Why VERACYTE INC (NASDAQ:VCYT) qualifies as a high growth stock. 
Via Chartmill
News headline image
Cathie Wood's Ark Invest Trims Palantir Again As Peter Thiel Co-Founded Firm's Stock Tumbles Nearly 15% In 2025 ↗
Cathie Wood-led Ark Invest sold 140,518 shares of Palantir and bought shares of Tempus AI Inc. The total value of the trades is about $9.1 million. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Should you consider VERACYTE INC (NASDAQ:VCYT) for high growth investing? ↗
Unlocking the high Growth Potential of VERACYTE INC (NASDAQ:VCYT). 
Via Chartmill
News headline image
Navigating 9 Analyst Ratings For Veracyte ↗
 
Via Benzinga
News headline image
Is NASDAQ:VCYT a Fit for high Growth Investing Strategies? ↗
Should you consider VERACYTE INC (NASDAQ:VCYT) for high growth investing? 
Via Chartmill
News headline image
Breaking Down Veracyte: 4 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Veracyte’s Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines
From Veracyte, Inc.
Via Business Wire
News headline image
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared? ↗
Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Smaller Cap Biotechs Are In Season: How Are We Doing? ↗
SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range. 
Via Talk Markets
News headline image
Veracyte Announces Third Quarter 2024 Financial Results
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Participate in Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024
From Veracyte, Inc.
Via Business Wire
News headline image
New Data Presented at ASTRO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Aggressive Prostate Cancer in African American Men
From Veracyte, Inc.
Via Business Wire
News headline image
Tempus AI Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating ↗
A Relative Strength Rating upgrade for Tempus AI shows improving technical performance. 
Via Investor's Business Daily
Topics Artificial Intelligence
News headline image
New Data Presented at ESMO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Named a Greater Bay Area Top Workplace by the San Francisco Chronicle
From Veracyte, Inc.
Via Business Wire
News headline image
Thermo Fisher Scientific Stock Sees RS Rating Jump To 81 ↗
Thermo Fisher Scientific stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 77 to 81. 
Via Investor's Business Daily
News headline image
Lumen Tech & Upstart Are Among Top 7 Mid Cap Gainers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio? ↗
Lumen, Upstart, ADMA, Sweetgreen, Veracyte, Clear Secure, and Core Scientific were best performers last week. Did you invest in them? 
Via Benzinga
News headline image
Diagnostic Tests Maker Veracyte's Q2 Is 'All-Around Very Good Quarter': Analysts Maintain Bullish View ↗
Veracyte reports Q2 sales of $114.43M, a 27% increase year over year, surpassing the $100.3 million consensus. Testing revenue rose 31% to $107 million, driven by strong performance of Decipher... 
Via Benzinga
News headline image
Shopify Posts Upbeat Earnings, Joins Axon Enterprise, Aspen Technology, Illumina, Global Payments And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
Pre-market stock movers are a hot topic on Wednesday and we have all of the latest news traders need to know about them this morning! 
Via InvestorPlace
News headline image
VCYT Stock Earnings: Veracyte Beats EPS, Beats Revenue for Q2 2024 ↗
VCYT stock results show that Veracyte beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Veracyte Announces Second Quarter 2024 Financial Results
From Veracyte, Inc.
Via Business Wire
News headline image
The 3 Best Personalized Nutrition Stocks to Buy Now ↗
Explore personalized nutrition stocks capitalizing on AI, machine learning and genetic profiling to provide targeted dietary solutions. 
Via InvestorPlace
Topics Artificial Intelligence
News headline image
Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024
From Veracyte, Inc.
Via Business Wire
News headline image
Trading SMID Biotech Stocks In A Volatile Market ↗
Trading SMID biotech stocks is difficult no matter what you know. Large cap biopharma with dividends should be the focus for non-traders. Healthcare and smaller caps are lagging within the context of a... 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story